About

Dr. Puja B Parikh, MD MPH, FACC, FAHA, FSCAI is an Interventional Cardiologist, the Director of the Transcatheter Aortic Valve Replacement (TAVR) Program at Stony Brook University Medical Center, and Professor of Medicine with Tenure at Stony Brook Renaissance School of Medicine. Her procedural expertise includes complex percutaneous coronary interventions, transcatheter aortic valve replacement, transcatheter closures of patent foramen ovale and atrial septal defect, transcatheter mitral valve interventions, paravalvular leak intervention, left atrial appendage closures, and endomyocardial biopsies. Dr. Parikh is actively involved in clinical research, serving as Principal Investigator in multiple cardiovascular clinical trials, and has authored over 120 peer-reviewed manuscripts in high-impact journals. She is a Fellow of the American College of Cardiology, American Heart Association, and Society of Coronary Angiography and Interventions, and has contributed to national guidelines and consensus statements in the field of cardiology. Her academic and professional activities include serving on editorial boards, participating in national writing groups, and lecturing at conferences worldwide, emphasizing her leadership in interventional cardiology.

Research topics

• Medicine
• Internal medicine
• Cardiology
• Surgery
• Radiology
• Anatomy
• Intensive care medicine

Selected publications

• 26-CCC-13960-ACC TAVR FOLLOWING VALVE-SPARING AORTIC ROOT REPLACEMENT - IMAGING AND PROCEDURAL CHALLENGES

  Journal of the American College of Cardiology · 2026-03-27

  article
  PublisherDOI

• Gene-Set and Proteomic Signatures Associated with Survival After In-Hospital Cardiac Arrest

  Resuscitation Plus · 2026-05-01

  articleOpen access

  In‑hospital cardiac arrest (IHCA) is associated with high mortality despite advances in resuscitation and post–cardiac arrest care. While individual inflammatory and neurologic biomarkers have been studied, less is known about coordinated proteomic and pathway‑level responses associated with survival after IHCA. In this prospective observational study, adult patients resuscitated after IHCA were enrolled at a tertiary academic medical center. Plasma samples were obtained at baseline (T0), 6 hours (T6), and 24 hours (T24) following return of spontaneous circulation (ROSC), when clinically feasible. High‑dimensional proteomic profiling was performed using the Olink® Explore 1536 platform. Survival‑associated proteins were identified using linear mixed‑effects models, and gene set enrichment analysis (GSEA) was performed to identify biologically coherent pathways. Ninety‑five patients were enrolled. Due to early mortality and clinical constraints, analyzable samples were obtained from overlapping patient subsets at T0 (n=24), T6 (n=21), and T24 (n=49). Individual protein‑level differences were limited at baseline. The greatest divergence between survivors and non‑survivors occurred at 6 hours, characterized by enrichment of immune‑metabolic, mitochondrial, and transcriptional pathways. At 24 hours, pathway enrichment narrowed toward chemokine signaling, GPCR‑mediated responses, and oxidative stress. Baseline pathway signals were nominal and did not meet false discovery rate thresholds. Survival following IHCA is associated with dynamic, time‑dependent proteomic and pathway‑level signatures, with the most pronounced biological divergence occurring early after resuscitation. These findings support the concept of time‑sensitive molecular phenotyping in post–cardiac arrest care and provide a foundation for future translational studies.

  PublisherDOI

• 26-CCC-19784-ACC TAV IN TAV IN SAV WITH BIOPROSTHETIC VALVE FRACTURE

  Journal of the American College of Cardiology · 2026-03-27

  articleSenior author
  PublisherDOI

• Correction to: 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

  Circulation · 2026-04-06 · 1 citations

  article
  PublisherDOI

• A Comparison of Three Commonly Used Catheter Strategies in Diagnostic Transradial Coronary Angiography

  The American Journal of Cardiology · 2026-04-22

  article
  PublisherDOI

• SCAI Expert Consensus Statement on Alternative Access for Transcatheter Aortic Valve Replacement

  Journal of the Society for Cardiovascular Angiography & Interventions · 2025-02-25 · 10 citations

  articleOpen access

  Transcatheter aortic valve replacement (TAVR) has become a widely accepted procedure for treating patients with symptomatic aortic stenosis. While transfemoral access remains the primary route due to its lower complication rates and favorable outcomes, a subset of patients have anatomical or clinical factors precluding this approach. For these patients, alternative access routes such as transaxillary, transcarotid, and transcaval provide viable options. This expert consensus statement aims to provide a comprehensive review of case selection, technical considerations, and outcomes associated with these alternative access routes in TAVR. Additionally, this document highlights the advancements in device technology and imaging guidance that have contributed to improving the safety and efficacy of alternative access TAVR. This consensus statement serves as a practical guide on best practices for interventional cardiologists, cardiothoracic surgeons, and heart teams in selecting patients and performing alternative access TAVR.

  PublisherDOI

• Impact of Calcified Raphe on TAVR in Bicuspid Patients: Predicting Redo-TAVR Feasibility and Virtual Planning Implications

  Circulation Cardiovascular Interventions · 2025-04-22 · 2 citations

  article

  BACKGROUND: Patients with bicuspid aortic stenosis who receive transcatheter aortic valve replacement (TAVR) may require subsequent valve interventions in their lifetime; however, the feasibility of redo-TAVR in this population is uncertain. We aimed to assess redo-TAVR feasibility in bicuspid patients and develop a predictive virtual valve planning algorithm. METHODS: We studied computed tomography scans of bicuspid patients who received a balloon-expandable transcatheter heart valve (THV) in the LRT trial (Low Risk TAVR). Redo-TAVR feasibility, determined by valve-to-coronary and valve-to-aorta measurements on 30-day computed tomography, was assessed according to raphe location and calcification. A virtual valve planning algorithm was developed using baseline and 30-day computed tomography scans. RESULTS: <0.001) due to favorable shifting of the THV away from the coronary ostia. A bicuspid virtual planning algorithm accounting for 83.4% THV underexpansion, resulting in an 11.9% taller frame and translation of the THV away from the calcified raphe (mean valve shift 6.6 mm) achieved 86.7% sensitivity and 88.9% specificity for predicting redo-TAVR feasibility. CONCLUSIONS: Calcified raphe in left/right cusp fusion shifts the THV away from the coronary ostia, reducing coronary obstruction risk during redo-TAVR. Underexpansion causing increased THV frame height and valve shifting is common in bicuspid patients; a virtual planning algorithm accounting for these aspects can accurately assess redo-TAVR risk. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02628899.

  PublisherDOI

• 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease

  Journal of the American College of Cardiology · 2025-12-18 · 24 citations

  article
  PublisherDOI

• Association of complete revascularization with safety and outcomes in elderly patients with multi-vessel coronary artery disease: a systematic review and meta-analysis

  IJC Heart & Vasculature · 2025-10-22

  reviewOpen access

  Background: The utility of complete revascularization has been well defined in young patients with acute coronary syndrome (ACS) and multivessel coronary artery disease (CAD). However, the clinical benefit in elderly patients remains unclear with current literature has yielded conflicting results. This meta-analysis aims to evaluate the association of complete versus culprit-only coronary revascularization with mortality in elderly patients with multivessel CAD. Methods: A literature search was conducted for studies reporting on outcomes after complete versus culprit-only revascularization in elderly patients with multivessel CAD presenting with ACS. The primary endpoint was all-cause mortality. The main secondary endpoint was cardiovascular (CV) mortality. The search included the following databases: PubMed, EMBASE, and Web of Science. The search was not restricted to time or publication status. Results: 14 studies with 11,994 elderly patients (7,236 with culprit-only, 4,758 with complete revascularization) met inclusion criteria. Mean follow-up duration was 29.0 months (range 12-56 months), mean age was 79.5 years old, 56.9% of patients were men, and mean left ventricular ejection fraction was 54.3%. Patients who underwent complete revascularization had significantly lower all-cause and CV mortality compared to culprit-only revascularization (OR 1.75, 95% CI 1.40-2.18; p < 0.001; OR 1.75, 95% CI 1.14-2.68; p = 0.01). Subgroup analysis demonstrated this association to be statistically significant for studies with cohorts presenting with non-ST segment elevation myocardial infarction (NSTEMI) and mixed cohorts that included NSTEMI and ST segment elevation myocardial infarction (STEMI) patients. However, there was no significant difference in risk of all-cause mortality with complete versus culprit-only revascularization in studies of only STEMI patients (OR 1.03, 95% CI 0.61-1.72; p = 0.92). Conclusion: Complete coronary revascularization is associated with lower risk of all-cause and CV mortality in elderly patients with multivessel CAD presenting with NSTEMI. However, there does not appear to be a difference in outcomes in patients presenting with STEMI.

  PublisherDOI

• 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

  Circulation · 2025-12-18 · 8 citations

  review

  AIM: The "2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease" provides recommendations to guide clinicians on the evaluation and treatment of adult patients with congenital heart disease. It incorporates new evidence to replace the "2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease." METHODS: A comprehensive literature search was conducted with a focus on literature published from 2017 to 2024; in some instances, older literature was also collected and reviewed. Clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants and published in English were identified from MEDLINE (via PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and CINAHL for selected searches. STRUCTURE: Recommendations from the "2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease" have been updated with new evidence to guide clinicians.

  PublisherDOI

Frequent coauthors

• Thomas V. Bilfinger

  Stony Brook Children's Hospital

  54 shared

• Jignesh Patel

  Stony Brook University Hospital

  53 shared

• Toby Rogers

  MedStar Washington Hospital Center

  49 shared

• Luis Gruberg

  John T. Mather Memorial Hospital

  48 shared

• Ajay J. Kirtane

  Cardiovascular Research Foundation

  40 shared

• Afshin Ehsan

  Brown University

  40 shared

• Federico M. Asch

  ProMedica Toledo Hospital

  40 shared

• Javed Butler

  Baylor Medical Center at Garland

  39 shared

Education

• B.S.

  New York University

• M.D.

  Stony Brook University Medical School

• M.D., Internal Medicine

  Stony Brook University Medical Center

• M.D., Cardiology

  Stony Brook University Medical Center

• M.D., Interventional Cardiology

  Columbia University Medical Center

• M.D., Structural and Valvular Heart Intervention

  Columbia University Medical Center

Awards & honors

• Society for Cardiovascular Angiography and Interventions Eme…
• American College of Cardiology Emerging Faculty Leadership A…
• American College of Cardiology Advanced Educator series (202…
• Sandra J. Lewis Mid-Career Women’s Leadership Institute (202…
• American College of Cardiology Young Investigator Finalist A…